PHVS
Pharvaris N.V. NASDAQ Listed Feb 5, 2021$29.68
Mkt Cap $1.9B
52w Low $14.59
91.2% of range
52w High $31.14
50d MA $27.77
200d MA $25.08
P/E (TTM)
-9.9x
EV/EBITDA
-6.5x
P/B
6.4x
Debt/Equity
0.0x
ROE
—
P/FCF
-10.2x
RSI (14)
—
ATR (14)
—
Beta
-2.58
50d MA
$27.77
200d MA
$25.08
Avg Volume
161.7K
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
J.H. Oortweg 21 · Leiden 2333 CH · NL
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 2, 2026 | AMC | -0.71 | -0.85 | -18.3% | 28.56 | +0.7% | -0.7% | -1.9% | -1.0% | -1.8% | -1.6% | — |
| Nov 12, 2025 | AMC | -0.78 | -0.70 | +10.3% | 25.81 | +0.3% | -6.0% | -2.9% | +5.8% | -3.8% | +2.4% | — |
| Aug 12, 2025 | AMC | -0.87 | -0.94 | -8.0% | 21.09 | +2.3% | +1.6% | +7.3% | -3.0% | -0.6% | +5.0% | — |
| May 13, 2025 | AMC | -0.80 | -0.89 | -11.2% | 16.11 | +1.7% | -0.2% | -1.0% | +4.1% | +0.8% | +3.4% | — |
| Mar 31, 2025 | AMC | — | -0.93 | — | 15.70 | -1.3% | -5.5% | +0.8% | -2.2% | -2.3% | -7.5% | — |
| Nov 13, 2024 | AMC | -0.66 | -0.85 | -28.8% | 20.04 | -0.1% | +2.5% | -1.0% | +2.8% | -2.0% | -0.0% | — |
| Aug 14, 2024 | AMC | -0.57 | -0.59 | -3.5% | 16.90 | +0.2% | +13.6% | -2.3% | -0.3% | -4.7% | -0.2% | — |
| May 8, 2024 | AMC | -0.56 | -0.56 | +0.0% | 20.85 | -0.6% | -1.3% | +4.3% | -1.4% | -1.7% | +6.2% | — |
| Apr 3, 2024 | AMC | -0.58 | -0.82 | -41.4% | 22.29 | -3.1% | +0.6% | +0.6% | +0.8% | +1.8% | -3.8% | — |
| Nov 2, 2023 | AMC | -0.67 | -0.63 | +6.0% | 17.18 | +1.7% | +7.6% | -8.2% | +2.4% | -1.0% | -2.6% | — |
| Aug 7, 2023 | AMC | -0.71 | -0.69 | +2.8% | 17.52 | +1.5% | +3.2% | -4.6% | +6.1% | +1.4% | -0.8% | — |
| May 8, 2023 | AMC | -0.81 | -0.72 | +11.1% | 9.26 | -0.6% | -8.2% | +0.0% | -3.4% | -2.6% | +1.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 7 | Wedbush | Maintains | Outperform → Outperform | — | $28.37 | $28.50 | +0.5% | -1.9% | -1.0% | -1.8% | -1.6% | +4.7% |
| Apr 6 | RBC Capital | Maintains | Outperform → Outperform | — | $28.56 | $28.75 | +0.7% | -0.7% | -1.9% | -1.0% | -1.8% | -1.6% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.00 | $27.49 | -1.8% | -4.4% | +0.1% | -3.6% | +0.3% | +2.3% |
| Dec 4 | BofA Securities | Maintains | Neutral → Neutral | — | $29.37 | $29.18 | -0.6% | -5.7% | -4.6% | -4.0% | -5.2% | -1.5% |
| Dec 4 | Oppenheimer | Maintains | Outperform → Outperform | — | $29.37 | $29.18 | -0.6% | -5.7% | -4.6% | -4.0% | -5.2% | -1.5% |
| Dec 4 | Guggenheim | Maintains | Buy → Buy | — | $29.37 | $29.18 | -0.6% | -5.7% | -4.6% | -4.0% | -5.2% | -1.5% |
| Dec 4 | Morgan Stanley | Maintains | Overweight → Overweight | — | $29.37 | $29.18 | -0.6% | -5.7% | -4.6% | -4.0% | -5.2% | -1.5% |
| Dec 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.12 | $24.13 | +0.0% | +21.8% | -5.7% | -4.6% | -4.0% | -5.2% |
| Nov 14 | Morgan Stanley | Maintains | Overweight → Overweight | — | $24.26 | $24.36 | +0.4% | -2.9% | +5.8% | -3.8% | +2.4% | -1.4% |
| Nov 13 | Wedbush | Maintains | Outperform → Outperform | — | $25.81 | $25.88 | +0.3% | -6.0% | -2.9% | +5.8% | -3.8% | +2.4% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.81 | $25.88 | +0.3% | -6.0% | -2.9% | +5.8% | -3.8% | +2.4% |
| Oct 9 | BofA Securities | Upgrade | Underperform → Neutral | — | $22.98 | $23.62 | +2.8% | -0.6% | -3.8% | +0.4% | -5.0% | +3.9% |
| Aug 13 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $21.09 | $21.58 | +2.3% | +1.6% | +7.3% | -3.0% | -0.6% | +5.0% |
| Jun 5 | Wedbush | Maintains | Outperform → Outperform | — | $16.62 | $16.61 | -0.1% | -3.4% | +4.5% | +7.4% | +0.5% | -5.9% |
| May 14 | Wedbush | Maintains | Outperform → Outperform | — | $16.11 | $16.38 | +1.7% | -0.2% | -1.0% | +4.1% | +0.8% | +3.4% |
| May 14 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $16.11 | $16.38 | +1.7% | -0.2% | -1.0% | +4.1% | +0.8% | +3.4% |
| Mar 3 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $15.90 | $16.05 | +0.9% | -3.6% | +0.8% | -3.0% | +3.1% | -2.8% |
| Jan 31 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $17.73 | $18.28 | +3.1% | -0.7% | -2.6% | +0.2% | +2.1% | +4.2% |
| Sep 6 | Oppenheimer | Maintains | Outperform → Outperform | — | $19.10 | $19.57 | +2.5% | +0.1% | +3.8% | +7.8% | -2.0% | -2.2% |
| Jul 3 | Oppenheimer | Maintains | Outperform → Outperform | — | $16.85 | $17.19 | +2.0% | +0.9% | -2.1% | +4.7% | -0.5% | +2.1% |
| May 9 | Wedbush | Maintains | Outperform → Outperform | — | $20.85 | $20.72 | -0.6% | -1.3% | +4.3% | -1.4% | -1.7% | +6.2% |
| Apr 22 | Morgan Stanley | Maintains | Overweight → Overweight | — | $19.16 | $19.50 | +1.8% | +8.9% | +2.0% | -0.2% | +7.2% | +2.5% |
| Apr 15 | Morgan Stanley | Maintains | Overweight → Overweight | — | $21.90 | $21.75 | -0.7% | -8.0% | +4.2% | +1.0% | -13.1% | +4.0% |
| Apr 11 | Wedbush | Maintains | Outperform → Outperform | — | $22.27 | $23.94 | +7.5% | +0.2% | -1.8% | -8.0% | +4.2% | +1.0% |
| Apr 11 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $22.27 | $23.94 | +7.5% | +0.2% | -1.8% | -8.0% | +4.2% | +1.0% |
| Mar 19 | Wedbush | Maintains | Outperform → Outperform | — | $24.83 | $24.85 | +0.1% | +4.7% | -4.1% | +0.3% | -2.6% | -12.7% |
| Mar 2 | Oppenheimer | Maintains | Outperform → Outperform | — | $39.23 | $38.48 | -1.9% | -1.2% | -0.6% | -12.7% | -14.5% | -5.9% |
| Mar 2 | BofA Securities | Maintains | Neutral → Neutral | — | $39.23 | $38.48 | -1.9% | -1.2% | -0.6% | -12.7% | -14.5% | -5.9% |
| Mar 2 | SVB Leerink | Maintains | Outperform → Outperform | — | $39.23 | $38.48 | -1.9% | -1.2% | -0.6% | -12.7% | -14.5% | -5.9% |
| Mar 2 | Morgan Stanley | Maintains | Overweight → Overweight | — | $39.23 | $38.48 | -1.9% | -1.2% | -0.6% | -12.7% | -14.5% | -5.9% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | Lu Peng | Chief Medical Officer | Sell | 143 | $31.00 | $4K | 66,083 | +0.30% | — |
| May 1, 2026 | Lu Peng | Chief Medical Officer | Sell | 14,023 | $30.16 | $423K | 66,226 | +0.30% | — |
| Apr 30, 2026 | Schikan Johannes Gerardus Christiaan Petrus | — | Sell | 670 | $31.03 | $21K | 355,167 | +1.97% | +1.38% |
| Apr 30, 2026 | Schikan Johannes Gerardus Christiaan Petrus | — | Sell | 28,400 | $30.30 | $861K | 355,837 | +1.97% | +1.38% |
| Apr 30, 2026 | Lesage Anne | Chief Early Development | Sell | 19,200 | $30.26 | $581K | 133,969 | +1.97% | +1.38% |
| Apr 30, 2026 | Lesage Anne | Chief Early Development | Sell | 18,000 | $30.26 | $545K | 56,450 | +1.97% | +1.38% |
| Apr 30, 2026 | Lesage Anne | Chief Early Development | Sell | 3,700 | $30.26 | $112K | 56,450 | +1.97% | +1.38% |
| Apr 30, 2026 | Lu Peng | Chief Medical Officer | Sell | 15,000 | $30.24 | $454K | 66,083 | +1.97% | +1.38% |
| Apr 29, 2026 | Schikan Johannes Gerardus Christiaan Petrus | — | Sell | 3,830 | $30.07 | $115K | 384,237 | +1.97% | +1.38% |
| Apr 29, 2026 | Lesage Anne | Chief Early Development | Sell | 3,700 | $30.08 | $111K | 56,450 | +1.97% | +1.38% |
| Apr 29, 2026 | Lu Peng | Chief Medical Officer | Sell | 3,733 | $30.06 | $112K | 62,350 | +1.97% | +1.38% |
No recent filings available.
Data updated apr 26, 2026 7:38pm
· Source: massive.com